Skip to Main Content
Skip Nav Destination

Often overlooked, non-cleavable linkers are an important tool in antibody–drug conjugate (ADC) discovery. This chapter discusses the use of non-cleavable linkers in the context of ADCs. Non-cleavable linkers have the advantage of being able to modulate the activity of the metabolite through modifications such as changing membrane permeability, potency, or affinity to transporters. Since non-cleavable linkers are a part of the active metabolite, changes in the linker will alter the active metabolite. Non-cleavable linkers do not have membrane permeability, are more stable, and are usually better tolerated in pre-clinical studies than their cleavable counterparts. Many ADCs with non-cleavable linkers have gone into the clinic, but the vast majority has utilized only two constructs (MCC-DM1 and mc-MMAF). Different platform toxicities such as liver toxicity (MCC-DM1) and ocular toxicity (mc-MMAF) have been observed; nonetheless, two ADCs using these non-cleavable linkers have been approved. This area has been relatively unexplored compared to cleavable linkers, and this chapter will discuss how the use of non-cleavable linkers can be an important tool in ADC discovery.

You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal